• 1
    Hjertquist SO, Vejlens L 1968 The glycosaminoglycans of dog compact bone and epiphyseal cartilage in the normal state and in experimental hyperparathyroidism. Calcif Tissue Res 2: 314333.
  • 2
    Gordon MY, Riley GP, Watt SM, Greaves MF 1987 Compartmentalization of a haematopoietic growth factor (GM-CSF) by glycosaminoglycans in the bone marrow microenvironment. Nature 326: 403405.
  • 3
    Dorshkind K 1990 Regulation of hemopoiesis by bone marrow stromal cells and their products. Annu Rev Immunol 8: 111137.
  • 4
    Siczkowski M, Andrew T, Amos S, Gordon MY 1993 Hyaluronic acid regulates the function and distribution of sulfated glycosaminoglycans in bone marrow stromal cultures. Exp Hematol 21: 126130.
  • 5
    Lee JY, Spicer AP 2000 Hyaluronan: A multifunctional, megaDalton, stealth molecule. Curr Opin Cell Biol 12: 581586.
  • 6
    Noble PW 2002 Hyaluronan and its catabolic products in tissue injury and repair. Matrix Biol 21: 2529.
  • 7
    Aruffo A, Stamenkovic I, Melnick M, Underhill CB, Seed B 1990 CD44 is the principal cell surface receptor for hyaluronate. Cell 61: 13031313.
  • 8
    Lesley J, Hyman R, Kincade PW 1993 CD44 and its interaction with extracellular matrix. Adv Immunol 54: 271335.
  • 9
    Zhu D, Bourguignon LY 1998 The ankyrin-binding domain of CD44s is involved in regulating hyaluronic acid-mediated functions and prostate tumor cell transformation. Cell Motil Cytoskeleton 39: 209222.
  • 10
    Bourguignon LY, Zhu H, Shao L, Chen YW 2001 CD44 interaction with c-Src kinase promotes cortactin-mediated cytoskeleton function and hyaluronic acid-dependent ovarian tumor cell migration. J Biol Chem 276: 73277336.
  • 11
    Bourguignon LY, Zhu H, Chu A, Iida N, Zhang L, Hung MC 1997 Interaction between the adhesion receptor, CD44, and the oncogene product, p185HER2, promotes human ovarian tumor cell activation. J Biol Chem 272: 2791327918.
  • 12
    Bourguignon LY, Zhu H, Shao L, Zhu D, Chen YW 1999 Rho-kinase (ROK) promotes CD44v(3,8–10)-ankyrin interaction and tumor cell migration in metastatic breast cancer cells. Cell Motil Cytoskeleton 43: 269287.
  • 13
    Bourguignon LY, Singleton PA, Zhu H, Zhou B 2002 Hyaluronan promotes signaling interaction between CD44 and the transforming growth factor beta receptor I in metastatic breast tumor cells. J Biol Chem 277: 3970339712.
  • 14
    Bourguignon LY 2001 CD44-mediated oncogenic signaling and cytoskeleton activation during mammary tumor progression. J Mammary Gland Biol Neoplasia 6: 287297.
  • 15
    Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ 1998 Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93: 165176.
  • 16
    Yasuda H, Shima N, Nakagawa N, Mochizuki SI, Yano K, Fujise N, Sato Y, Goto M, Yamaguchi K, Kuriyama M, Kanno T, Murakami A, Tsuda E, Morinaga T, Higashio K 1998 Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): A mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology 139: 13291337.
  • 17
    Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashio K, Udagawa N, Takahashi N, Suda T 1998 Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 95: 35973602.
  • 18
    Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Boyle WJ 1997 Osteoprotegerin: A novel secreted protein involved in the regulation of bone density. Cell 89: 309319.
  • 19
    Burgess TL, Qian Y, Kaufman S, Ring BD, Van G, Capparelli C, Kelley M, Hsu H, Boyle WJ, Dunstan CR, Hu S, Lacey DL 1999 The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. J Cell Biol 145: 527538.
  • 20
    Tan KB, Harrop J, Reddy M, Young P, Terrett J, Emery J, Moore G, Truneh A 1997 Characterization of a novel TNF-like ligand and recently described TNF ligand and TNF receptor superfamily genes and their constitutive and inducible expression in hematopoietic and non-hematopoietic cells. Gene 204: 3546.
  • 21
    Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli C, Morony S, Oliveira-dos-Santos AJ, Van G, Itie A, Khoo W, Wakeham A, Dunstan CR, Lacey DL, Mak TW, Boyle WJ, Penninger JM 1999 OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397: 315323.
  • 22
    Kostenuik PJ, Shalhoub V 2001 Osteoprotegerin: A physiological and pharmacological inhibitor of bone resorption. Curr Pharm Des 7: 613635.
  • 23
    Boyle WJ, Simonet WS, Lacey DL 2003 Osteoclast differentiation and activation. Nature 423: 337342.
  • 24
    Cao J, Venton L, Sakata T, Halloran BP 2003 Expression of RANKL and OPG correlates with age-related bone loss in male C57BL/6 mice. J Bone Miner Res 18: 270277.
  • 25
    Khaldoyanidi S, Moll J, Karakhanova S, Herrlich P, Ponta H 1999 Hyaluronate-enhanced hematopoiesis: Two different receptors trigger the release of interleukin-1beta and interleukin-6 from bone marrow macrophages. Blood 94: 940949.
  • 26
    Kostenuik PJ, Harris J, Halloran BP, Turner RT, Morey-Holton ER, Bikle DD 1999 Skeletal unloading causes resistance of osteoprogenitor cells to parathyroid hormone and to insulin-like growth factor-I. J Bone Miner Res 14: 2131.
  • 27
    Nauman EA, Satcher RL, Keaveny TM, Halloran BP, Bikle DD 2001 Osteoblasts respond to pulsatile fluid flow with short-term increases in PGE(2) but no change in mineralization. J Appl Physiol 90: 18491854.
  • 28
    Halloran BP, Ferguson VL, Simske SJ, Burghardt A, Venton LL, Majumdar S 2002 Changes in bone structure and mass with advancing age in the male C57BL/6J mouse. J Bone Miner Res 17: 10441050.
  • 29
    Wronski TJ, Cintron M, Dann LM 1988 Temporal relationship between bone loss and increased bone turnover in ovariectomized rats. Calcif Tissue Int 43: 179183.
  • 30
    Turner R 1994 Cancellous bone turnover in growing rats: Time-depemdemt changes in association between calcein label and ostoeblasts. J Bone Miner Res 9: 14191424.
  • 31
    Isacke CM, Yarwood H 2002 The hyaluronan receptor, CD44. Int J Biochem Cell Biol 34: 718721.
  • 32
    Nakamura H, Kenmotsu S, Sakai H, Ozawa H 1995 Localization of CD44, the hyaluronate receptor, on the plasma membrane of osteocytes and osteoclasts in rat tibiae. Cell Tissue Res 280: 225233.
  • 33
    Huges D, Salter D, Simpson R 1994 CD44 expression in human bone: A novel marker of osteocyte differentiation. J Bone Miner Res 9: 3944.
  • 34
    Nakamura H, Ozawa H 1996 Immunolocalization of CD44 and the ERM in bone cells of mouse tibiae. J Bone Miner Res 11: 17151722.
  • 35
    Knudsen W, Chow G, Knudsen C 2001 CD44-mediated uptake and degradation of hyaluronan. Matrix Biol 21: 1523.
  • 36
    Jamal HH, Aubin JE 1996 CD44 expression in fetal rat bone: In vivo and in vitro analysis. Exp Cell Res 223: 467477.
  • 37
    Chellaiah MA, Biswas RS, Rittling SR, Denhardt DT, Hruska KA 2003 Rho-dependent Rho kinase activation increases CD44 surface expression and bone resorption in osteoclasts. J Biol Chem 278: 2908629097.
  • 38
    Protin U, Schweighoffer T, Jochum W, Hilberg F 1999 CD44-deficient mice develop normally with changes in subpopulations and recirculation of lymphocyte subsets. J Immunol 163: 49174923.
  • 39
    Midura RJ, Evanko SP, Hascall VC 1994 Parathyroid hormone stimulates hyaluronan synthesis in an osteoblast-like cell line. J Biol Chem 269: 1320013206.